Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Total Non-Current Liabilities (2018 - 2025)

Bioadaptives' Total Non-Current Liabilities history spans 8 years, with the latest figure at $617153.0 for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 8.24% to $617153.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $617153.0, a 8.24% decrease, with the full-year FY2025 number at $617153.0, down 8.24% from a year prior.
  • Total Non-Current Liabilities hit $617153.0 in Q4 2025 for Bioadaptives, down from $622164.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for BDPT hit a ceiling of $1.3 million in Q3 2021 and a floor of $502577.0 in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $711729.7 across 5 years, with a median of $678568.0 in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 137.88% in 2021 and later decreased 12.97% in 2024.
  • Tracing BDPT's Total Non-Current Liabilities over 5 years: stood at $684582.0 in 2021, then rose by 17.15% to $801959.0 in 2022, then fell by 3.64% to $772757.0 in 2023, then decreased by 12.97% to $672554.0 in 2024, then dropped by 8.24% to $617153.0 in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BDPT at $617153.0 in Q4 2025, $622164.0 in Q3 2025, and $547177.0 in Q2 2025.